Written by: Deng Yinglin
2019-12-19 12:08Last updated: 2019-12-19 15:20
At present, most patients in Hong Kong use tumor imaging and surgery to extract tumor tissues from patients for laboratory tests to detect cancer. The City University Biomedical Research Team announced today (19th) that a new detection technology has been developed. Cancer cells can be sorted in about five minutes. If the sample is found to contain 4 or more cancer cells, it means a greater chance of cancer. The team pointed out that the accuracy rate of detecting cancer cells can be as high as 90%, but the current stage of the examination failed to reflect the source of the cancer cells, that is, the source of the disease could not be found in the same examination.
Yu Weijian, senior associate researcher at CityU's Department of Biomedicine, pointed out that the new technology developed by the team can isolate blood cells and screen cancer cells in five minutes to detect early cancers. (Photo by Deng Yinglin)
Research team members include Zou Heng and Yu Weijian, senior associate researchers in the Department of Biomedical Sciences of CityU. They pointed out that the breakthrough cancer early screening and disease monitoring technology developed by the team can detect cancer 3 to 6 months earlier than imaging examination, and even tumors as small as 0.1 mm can be detected, which is the fastest technology in the world with the same principle.
In addition to being diagnosed with cancer in a short period of time, the test can also monitor the efficacy of the drug in the course of treatment, test whether the patient is resistant to the drug, and analyze early if there is a need to change the drug or change the cancer treatment plan. The relevant technology is licensed to the start-up company "Jingzhun Biopharmaceutical Group Co., Ltd." established by the team in 2017. The product has been certified by the State Food and Drug Administration (NMPA) of China and is expected to receive the EU in vitro diagnostic medical device (IVDD) next month. CE certification.
The research team at the CityU School of Biomedicine has developed a new detection technology that only takes about 4 ml of blood to sort out cancer cells in about five minutes. (Photo by Deng Yinglin)
Cancer is the number one killer in Hong Kong, and the number of new cases has been increasing year by year. The Cancer Statistics Centre of the Hospital Authority previously released 2017 cancer data. The number of new cases was as high as 33,075, a record high of at least nine years.
CityU's biomedical research team has previously collaborated with other local and overseas scholars to develop new technologies through the "microfluidic chip cell manipulation and detection technology platform", which uses microfluidic chips to remove cancer cells and other waste fluids in the blood. Separately, count the number of cancer cells in the sample. If 4 or more cancer cells are found, there is a great chance of getting cancer. The detection method is simple, only about 4 ml of blood is drawn and placed in the machine, and cancer cells can be sorted out in about five minutes to obtain a report.
Yu Weijian, a senior associate researcher at the Department of Biomedical Sciences of CityU, pointed out that the breakthrough cancer screening and disease monitoring technology developed by the team is through micro-control technology and cell surface markers. Because the thickness of micro-fluidic chips is similar to human blood vessels, Cancer cells can be identified directly from the blood. The relevant technology has been tested in a number of hospitals or clinics in Hong Kong and the Mainland (ie the comparison of health and breast cancer, lung cancer and colorectal cancer patients), with an accuracy rate of 90%.
New technology can detect cancers other than leukemia, brain tumors or hemangiomas. (Photo by Deng Yinglin)
The team said that the new technology can detect cancers other than leukemia, brain tumors or hemangiomas, and that it can be used by people regardless of age, gender, medical history and long-term medication. In addition to the fastest results in the same principle technology worldwide, cancer can be found 3 to 6 months earlier than imaging examinations. Even tumors as small as 0.1 mm can be found. The accuracy rate of detecting the earliest (stage 1) cancer is up to About 75%, more than double the industry.
Zou Heng, a senior associate researcher at CityU ’s Department of Biomedicine, pointed out that in general, 0.1 mm tumors have grown for about 10 years or more, but it will take about two years to grow to 0.5 mm. Early detection can improve patient awareness and monitor the disease. It may not necessarily be cancer, but it may be inflammation, immune system problems, or tumors. "Because the new technology can only find cancer cells and cannot identify the source of cancer cells, if you are diagnosed or have cancer, you need to do other tests. Find out the cause.
Yu Weijian, a senior associate researcher at CityU's Department of Biomedicine, points out that new detection technologies can also help to follow up on cancer treatment. (Photo by Deng Yinglin)
In addition to helping to screen out cancer patients early, the new technology can also be used to follow up cancer treatment and reduce the chance of spread. Yu Weijian pointed out that the test can also monitor the efficacy of the drug in the treatment process in order to analyze early if there is a need for a drug change or a cancer treatment plan.
Yu Weijian described that liquid biopsy has advantages in the next ten years. "It is an important time to transform technology into products." Therefore, they established a start-up company "Jingzhun Biopharmaceutical Group Co., Ltd." in 2017. This technology has been licensed to the company. . The machine has been certified by China's State Food and Drug Administration (NMPA). It is expected that it will be awarded the EU in vitro diagnostic medical device (IVDD) CE certification next month.
One of the team members Huang Yuanjie revealed that it is currently negotiating with medical institutions in Hong Kong, Macau, Germany, Portugal, Spain, Turkey and other places. It is expected that it can be put into the Hong Kong market as soon as 2020, with an average cost of about 10,000 per inspection. To 15,000 yuan, in the future, the same test will be studied to test whether patients will be sensitive or resistant to drugs.
1 drop of urine test for 15 types of cancer! New technology will be launched next year, "zero period" knows the accuracy rate is more than 80%
[Lung cancer treatment] Third-line EGFR lung cancer target drugs may be considered for first-line treatment
[Medical examination] 3 kinds of tests found that early cancer has a family history of high risk and early cancer test index
City University Cancer